Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study tests simpler method for spinal cord stimulator placement

NCT ID NCT02986074

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested two different methods for placing a spinal cord stimulator (SCS) lead in people with chronic back pain. One method uses the patient's sensation of tingling (paresthesia) to guide placement, while the other uses the spine's natural midline as a guide. Sixty adults with failed back surgery syndrome and severe pain took part. The goal was to see if the simpler, anatomy-based method works as well as the standard technique.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
spinal cord stimulation device
What this could lead to
If successful, this could show that a simpler, anatomy-based lead placement works as well as the standard method, potentially making the procedure easier and more consistent.
What could go wrong
This is a small, completed study with 60 participants comparing two techniques. Results may not apply to all pain types or patients, and individual outcomes can vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Started

Nov 2016

Finished

Aug 2019

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subject is able to provide informed consent to participate in the study; * Subject is 18 years of age or older; * Subject has failed to respond to at least 6 months of conventional treatment including pharmacological treatment, physical therapy, epidural injections and/or radiofrequency therapy as per NICE Tag 0159; * FBSS subjects with predominant low back pain; * Subject has a lower back pain intensity of at least 6.0 out of 10.0 on the VAS at baseline; * Subject is on stable pain medications with a total opioid equivalent of 120 mgs a day or less for at least 28 days prior to enrolling in this study, and is willing to stay on those medications with no dose adjustments until activation of the permanently implanted SCS device; * Subject's medical record has been evaluated by the Investigator to ensure that the subject is a good candidate for a neurostimulation system; * Subject is willing to cooperate with the study requirements including compliance with the regimen and completion of all office visits; * Female candidates of child-bearing potential agree to commit to the use of an effective method of contraception (including but not limited to sterilization, barrier devices, oral contraceptives, intrauterine devices (IUDs), condoms, rhythm method, or abstinence) for the duration of the study Exclusion Criteria: * Subjects with significant scoliosis even if surgically corrected * Subject is currently participating in a clinical investigation that includes an active treatment arm; * Subject has been implanted with or participated in a trial period for a neurostimulation system; * Subject has an infusion pump; * Subject has evidence of an active disruptive psychological or psychiatric disorder as determined as per standard of care; * Subject has a current diagnosis of a coagulation disorder, bleeding diathesis, progressive peripheral vascular disease or uncontrolled diabetes mellitus; * Subject has a current diagnosis of a progressive neurological disease as determined by the Investigator; * Subject is immunocompromised; * Subject has an existing medical condition that is likely to require repetitive MRI evaluation in the future (i.e. epilepsy, stroke, multiple sclerosis, acoustic neuroma, tumor); * Subject has history of cancer requiring active treatment in the last 12 months; * Subject has an existing medical condition that is likely to require the use of diathermy in the future; * Subject has documented history of allergic response to titanium or silicone; * Subject has a documented history of substance abuse (narcotics, alcohol, etc.) or substance dependency in the 6 months prior to baseline data collection; * Female candidates of child bearing potential that are pregnant (confirmed by positive urine/blood pregnancy test).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic pain are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Seacroft Hospital

    Leeds, Yorkshire and the Humber, LS14 6UH, United Kingdom

  • St. Thomas Hospital

    London, SE1 7EH, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.